Q3 FY2026 · ended Sep 30, 2026 · Revenue $151.75M, +15.1% YoY · Filed Nov 5, 2026
Veracyte, Inc. (VCYT) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $151.8 million and net income of $31.5 million. Free cash flow was $37.9 million. As of Sep 30, 2026 it held $199.8 million in cash and investments and $40.7 million in total debt.
Revenue
$151.75M
+15.1% vs year-ago quarter
Net income
$31.50M
+64.6% vs year-ago quarter
Operating cash flow
$40.26M
-10.1% vs year-ago quarter
Free cash flow
$37.92M
-9.6% vs year-ago quarter
EPS
$0.38
+58.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
80.70M
+2.1% vs year-ago quarter
Net cash
$159.09M
Q3 FY2026
Operating margin
17.1%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- VCYT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1384101
- Former names
- CALDEROME INC (until Feb 27, 2008)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $151.8M | $150.3M | $139.1M | $140.6M | $131.9M |
| Operating income | $16.6M | $23.0M | $22.6M | $37.2M | $22.9M |
| Net income | $31.5M | $25.5M | $28.7M | $41.1M | $19.1M |
| Diluted EPS | $0.38 | $0.31 | $0.35 | $0.50 | $0.24 |
| Operating cash flow | $40.3M | $45.8M | $35.2M | $52.6M | $44.8M |
| Free cash flow | $37.9M | $43.0M | $32.3M | $48.8M | $42.0M |
| Total assets | $1.6B | $1.5B | $1.4B | $1.4B | $1.4B |
| Total liabilities | $140.0M | $98.0M | $92.0M | $96.4M | $110.1M |
| Stockholders' equity | $1.4B | $1.4B | $1.3B | $1.3B | $1.3B |
| Cash and investments | $199.8M | $299.5M | $263.1M | $412.9M | $315.6M |
| Total debt | $40.7M | $40.1M | $39.3M | $39.7M | $40.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 1003 Veracyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.